Vitamin B12 is an essential nutrient with a fragile uptake route, and that fragility, not diet, explains most shortfalls past middle age. Correcting a genuine shortfall works cleanly; tablets match injections. Adding B12 on top of an adequate supply moves the blood marker but largely not the outcomes. Harm signals are real but narrow. (Full Review)

Protocol

Oral high-dose alternative

1,000–2,000 µg daily by mouth

Matches injection even without intrinsic factor; roughly 1% crosses passively.

Conventional repletion standard

Hydroxocobalamin 1 mg intramuscularly, alternate days for two weeks

Then every two to three months where irreversible.

Baseline biomarkers drive the regimen

Methylmalonic acid above 250 nmol/L or active-B12 below 50 pmol/L

Identifies who needs treatment; a normal serum value with raised methylmalonic acid still warrants repletion.

Time to effect

Blood counts

Within a week, normal by 8 weeks

Megaloblastic anemia reverses.

Serum B12

2–3 months

On 1,000–2,000 µg daily by mouth.

Neurological recovery

6–12 months

Often incomplete; damage beyond a year is frequently permanent.

Benefits

High: Correction of vitamin B12 deficiency and reversal of megaloblastic anemia

Medium: Improvement of peripheral neuropathy symptoms; slower cognitive decline during long-term B-vitamin supplementation; fewer strokes where food is not folic-acid fortified

Low: Reduction of elevated blood homocysteine; preservation of gait and fracture resistance in the very old

Speculative: Slower epigenetic aging at mid-range B12 status; mitochondrial and skeletal-muscle support via adenosylcobalamin

Contraindications

Nitrous oxide in untreated deficiency

Cyanocobalamin in Leber's hereditary optic neuropathy

Documented cobalamin or cobalt hypersensitivity

Polycythemia vera and other myeloproliferative neoplasms

High-dose folic acid, B6 and B12 in diabetic nephropathy or chronic kidney disease (eGFR below 60 mL/min/1.73 m²)

Serum B12 above 600 pmol/L unexplained by supplementation, pending investigation

Key Interactions

Metformin

Proton pump inhibitors (omeprazole, pantoprazole)

H2-receptor antagonists (famotidine, cimetidine)

Colchicine, neomycin, chloramphenicol, aminosalicylic acid

Antacids and calcium carbonate

High-dose ascorbic acid (above 1 g)

Folic acid supplements above 1 mg daily

Additive homocysteine-lowering supplements (L-Methylfolate, B6, betaine)

Loop and thiazide diuretics (furosemide, hydrochlorothiazide) during rapid repletion of severe anemia

Risk & Side Effects

High: Increased cancer incidence and mortality with combined folic acid and vitamin B12 regimens

Medium: Faster kidney function decline and more vascular events in diabetic kidney disease; elevated serum B12 as a marker of higher all-cause mortality

Low: Acne-like eruptions and skin flares; hypersensitivity reactions to injectable and oral cobalamin; hypokalemia during rapid repletion of severe megaloblastic anemia

Speculative: Cyanide load from high-dose cyanocobalamin in advanced kidney failure

Monitoring

Marker	Target	Why
Serum total vitamin B12	500–800 pg/mL (370–590 pmol/L)	First-line measure of circulating supply
Methylmalonic acid	Below 250 nmol/L	Rises before serum B12 falls; shows cellular supply
Active-B12 (holotranscobalamin)	Above 50 pmol/L	The fraction of B12 cells can take up
Total homocysteine	Below 9 µmol/L	Integrates B12, folate, B6 and kidney status
Complete blood count with mean corpuscular volume	Mean corpuscular volume 82–90 fL	Detects and tracks the megaloblastic change
Serum folate and red cell folate	Red cell folate 400–800 ng/mL	Interpret alongside B12; the two are inseparable
eGFR with serum creatinine	Above 60 mL/min/1.73 m²	Gates high-dose combined regimens; calibrates methylmalonic acid
Serum potassium	3.8–4.5 mmol/L	Guards against the potassium shift during rapid repletion
Intrinsic factor and parietal cell antibodies	Negative	Identifies pernicious anemia as the cause

Cadence: Full panel at baseline before the first dose; blood count and serum B12 at 8 weeks; homocysteine and methylmalonic acid at 3 months; then the full panel every 6–12 months while supplementation continues. Annual testing on metformin or acid suppression; yearly kidney function on combined high-dose regimens.

Qualitative Assessment

Energy through the afternoon, and whether exercise tolerance recovers as counts normalise
Numbness, tingling or burning in hands and feet, and whether it is receding or progressing
Balance in the dark or with eyes closed, an early indicator of spinal cord involvement
Cognitive clarity, word-finding and short-term recall over months rather than days
Mood stability and irritability, which can shift before any neurological sign appears
Sore or smooth tongue and mouth ulceration, which resolve quickly on repletion
Skin: new acne-like eruptions after starting, which point toward reducing the dose

Vitamin B12 for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment